Khaled Musallam/LinkedIn
Nov 20, 2025, 16:47
Khaled Musallam Takes on The Role as Chief of Cell/Gene Therapies and Hematology at Burjeel Cancer Institute
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Priviliged to be working with my friend Prof.Humaid Al-Shamsi to build on the strong foundations of BCI and lead the expansion of hematology services across the network, including dedicated programs in both classical (benign) and malignant hematology, and advanced cell and gene therapies through innovative clinical trials and strategic international partnerships with industry innovators.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 17:50Elad AsherÖ‰ STORM-PE Shows Functional Benefits of Thrombectomy
-
Oct 16, 2026, 17:32Shruthi Narayan: STORM-PE and STRIKE-PE Studies Advance Understanding of Recovery After Pulmonary Embolism
-
Oct 16, 2026, 17:22Wolfgang MiesbachÖ‰ What a Near-Perfect FISH Score Fails to See
-
Oct 16, 2026, 17:06Troels Wienecke: Connecting Myeloproliferative Disease and Ischemic Stroke
-
Oct 16, 2026, 17:03Only 5 Days Left to Submit Your Research for EAHAD 2027
-
Oct 16, 2026, 16:48Abdul Rahman: Reticulocyte Count and Bone Marrow Activity
-
Oct 16, 2026, 16:44DOAC Adherence in Stroke Patients With Atrial Fibrillation – International Journal of Stroke
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards